Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1387-1395

  Villa, Diego ^a   Gubbay, Jonathan ^b   Robert Sutherland, D ^c   Laister, Robert ^a   McGeer, Allison ^d   Cooper, Curtis ^e   Fortuno III, Edgardo S ^f   Xu, Wei ^a   Shi, Lily ^b   Kukreti, Vishal ^a   Crump, Michael ^a   Kuruvilla, John ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b PUBLIC HEALTH ONTARIO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

H1N1; Influenza; Lymphoma; Rituximab; Vaccination

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 5; RITUXIMAB; VASCULOTROPIN;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BODY MASS; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

ADULT; AGED; ANTIBODIES, VIRAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LEUKEMIA, LYMPHOID; LYMPHOMA; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84879335701     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.742524     Document Type: Article

References (42)

1. Centers for Disease Control and Prevention (CDC). Outbreak of swine-origin influenza A (H1N1) virus infection-Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 467-470.
2. Smith G J, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009;459:1122-1125.
3. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009; 84: 249-257.
4. Campbell A, Rodin R, Kropp R, et al. Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza. CMAJ 2010;182:349-355.
5. World Health Organization. Pandemic (H1N1) 2009-Update 69. 2009. Available from: http://www.who.int/csr/don/2009-10-09/en/index.html
6. Centers for Disease Control and Prevention (CDC). Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep 2009; 58: 1100-1101.
7. Greenberg M E, Lai M H, Hartel G F, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361: 2405-2413.
8. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361:2424-2435.
9. Product Information Leaflet Arepanrix H1N1 AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine Version 2, approved 29 January 2010. Ottawa: Health Canada;2009.
10. World Health Organization. W orld Health Organization manual on animal influenza diagnosis and surveillance. Global Influenza Programme. Geneva: WHO; 2002.
11. European Agency for the Evaluation of Medicinal Products. N ote for guidance on harmonisation of requirements for influenza vaccines. EMEA. Committee for Proprietary Medicinal Products. London, 12 March 1997.
12. European Agency for the Evaluation of Medicinal Products. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. EMEA. Committee for Human Medicinal Products. London, 24 January 2007.
13. US Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. FDA. Center for Biologics Evaluation and Research. May 2007.
14. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35:69-75. (Pubitemid 9096975)
15. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375: 56-66.
16. Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010;375:41-48.
17. Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010;28:1740-1745.
18. V ajo Z, T amas F, S inka L, et al. S afety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010;375:49-55.
19. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361: 2414-2423.
20. de Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2012; 96: 307-314.
21. Engelhard D, Zakay-Rones Z, Shapira MY, et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 2011; 29: 1777-1782.
22. Hottinger AF, George AC, Bel M, et al. A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. Oncologist 2012; 17: 436-445.
23. Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011;17:434-438.
24. Mariotti J, Spina F, Carniti C, et al. Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies. Eur J Haematol 2012; 89: 111-119.
25. Brydak LB, Machala M, Centkowski P, et al. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma. Vaccine 2006; 24: 6620-6623. (Pubitemid 46107150)
26. Mazza JJ, Yale SH, Arrowood JR, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005;3:214-220.
27. A vetisyan G, A schan J, H assan M, et al. E valuation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008;86:257-263.
28. Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993;11 : 1-5. (Pubitemid 23086839)
29. L jungman P, A vetisyan G. I nfluenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 2008;42:637-641.
30. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 2005;130:96-98. (Pubitemid 40979139)
31. van der Velden AM, Mulder AH, Hartkamp A, et al. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med 2001;12:420-424. (Pubitemid 32823520)
32. Lo W, Whimbey E, Elting L, et al. Antibody response to a twodose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993; 12: 778-782. (Pubitemid 23326561)
33. Beck MA. Influenza and obesity: will vaccines and antivirals protect? J Infect Dis 2012;205:172-173.
34. Talbot HK, Coleman LA, Crimin K, et al. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine 2012; 30: 3937-3943.
35. Yri OE, Torfoss D, Hugnes O, et al. Lymphoma patients treated with rituximab-containing regimens do not achieve protective serological responses to H1N1 influenza virus after vaccination. Ann Oncol 2011; 22(Suppl. 4): iv131.
36. Takata T, Suzumiya J, Ishikawa T, et al. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop 2009;49:9-13.
37. Eriksson J C, Cox R J, Szyszko E, et al. Local and systemic cytokine and chemokine responses after parenteral influenza vaccination. Influenza Other Respi Viruses 2007; 1: 139-146.
38. S hahid Z, K leppinger A, G entleman B, et al. C linical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010;28:6145-6151.
39. B ermejo-Martin J F, O rtiz de Lejarazu R, P umarola T, et al. Th 1 and Th 17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 2009;13:R201.
40. Pauksen K, Sjolin J, Linde A, et al. Th 1 and Th 2 cytokine responses after measles antigen stimulation in vitro in bone marrow transplant patients: response to measles vaccination. Bone Marrow Transplant 1997;20:317-323. (Pubitemid 27389241)
41. Dearing S. H1N1 vaccine safety becomes an issue in Canada. Digital Journal 23 October 2009;Sect. Article 280927.
42. Weeks C. Low H1N1 vaccination rate alarms health experts. The Globe and Mail 28 May 2010;Sect. Article 1583841.